Phase I study to evaluate cellular adoptive immunotherapy using autologous CD8+ antigen-specific T cell clones [cytotoxic-T-lymphocytes] following cyclophosphamide conditioning for patients with metastatic melanoma.

Trial Profile

Phase I study to evaluate cellular adoptive immunotherapy using autologous CD8+ antigen-specific T cell clones [cytotoxic-T-lymphocytes] following cyclophosphamide conditioning for patients with metastatic melanoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2012

At a glance

  • Drugs Aldesleukin (Primary) ; Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Cytotoxic T lymphocytes (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Mar 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top